SITE008-0022

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2022-03-08

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-24 (study day 90); relationship: N

severe assessed

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-07-18 (study day 114); relationship: N

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-12 (study day 170); relationship: N

moderate assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-16 (study day 174); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-01-06 (study day 286); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-23 (study day 334); relationship: N

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-19 (study day 358); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-10 (study day 563); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-12-05 (study day 619); relationship: N

Data queries

No data queries.